Royalty Report: Drugs, HIV / AIDs, Disease – Collection: 56027


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 8

Primary Industries

  • Drugs
  • HIV / AIDs
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • Antibody
  • Drug Testing
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 56027

License Grant
The Company acquired the rights to the HIV viral-entry inhibitor drug candidate PRO 140, a humanized anti-CCR5 monoclonal antibody, as well as certain other related assets, including the existing inventory of bulk PRO 140 drug product, intellectual property, certain related licenses and sublicenses, and U.S. Food and Drug administration regulatory filings.
License Property
PRO 140 belongs to a class of HIV therapies known as entry inhibitors. These therapies block HIV from entering into and infecting certain cells. We believe that monoclonal antibodies are a new emerging class of therapeutics for the treatment of HIV. Seven clinical trials demonstrating safety and efficacy for PRO 140 have been completed.
Field of Use
The rights granted apply to the drug industry.

IPSCIO Record ID: 1395

License Grant
The new Licensee acquired from previous Licensee its proprietary HIV viral-entry inhibitor drug candidate PRO 140, a humanized anti-CCR5 monoclonal antibody, as well as certain other related assets, including the existing inventory of bulk PRO 140 drug product, intellectual property, certain related licenses and sublicenses, and U.S. Food and Drug Administration regulatory filings. As part of this agreement, the original Licensee obligations under the 1999 agreement with the Licensor were transferred to new Licensee.

IPSCIO Record ID: 139546

License Grant
The Canadian Company reacquired the 50% interest in the Antibody 1F7 acquired by Licensor.
License Property
The monoclonal antibody 1F7 has several important effects on both humoral (antibody-mediated) and cellular immunity mechanisms  that make it an ideal candidate for an HIV therapy.  The anti-idiotypic antibody 1F7 selectively inhibits cytotoxic T-cells activated in HIV-1 infection.  Immunol Cell Biol 78(1), 20-7.
Field of Use
This agreement pertains to the drug industry related to its use as a therapeutic for the prevention and treatment of HIV infection.

IPSCIO Record ID: 289819

License Grant
With this agreement, Licensor will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications, while Licensee has been granted an exclusive license to market and distribute leronlimab.
License Property
Leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.
Field of Use
The field of use is for the treatment of HIV.

IPSCIO Record ID: 26363

License Grant
The Company entered into a worldwide exclusive patent license agreement with the Licensor, government public health organization, concerning composition of matter for BlockAide/CR.
License Property
BlockAide/CR&#-3884; is a peptide-based drug that is intended to work by blocking viral entry and infection of human immune system cells.

The patents covering a peptide product, known as BlockAide, for the treatment and prevention of HIV.

Field of Use
The rights granted apply to the medical industry relating to human infections.

IPSCIO Record ID: 25977

License Grant
The Canadian Licensor will grant the Licensee an exclusive sub-license option on technology to use the technology in Licensor's antibody improvement platforms. The technology grant will also include the non-exclusive use to make genetically engineered forms or humanized forms and to derive fully human antibodies.
Field of Use
Licensee will use best efforts to promptly commercialize the technology as permitted in this SubLicense.

IPSCIO Record ID: 28080

License Grant
Licensee holds exclusive rights to a number of patents that have issued in the U.S. and the EU covering methods for the manufacture of our ANX-201 product candidate and of various analogs and derivatives thereof, and the use of ANX-201 in connection with the HIV.
License Property
ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) for treatment of resistant HIV-infected patients. ANX-201 has shown activity against HIV drug-resistant clinical isolates in preclinical studies. The resistance profile of ANX-201 is unique among approved RTIs and has been shown to resensitize NRTI resistant viruses. In preclinical studies, anti-retroviral activity of ANX-201 has demonstrated synergistic activity with NRTIs suggesting potential clinical benefits of combination therapy.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 6565

License Grant
The Licensor today announced the execution of a License Agreement for elvucitabine, the Company’s nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) infection and human immunodeficiency virus (HIV) infection with the Licensee.

The exclusive License grants the Licensee the right, through its Chinese joint venture with Tianjing Institute of Pharmaceutical Research, to clinically develop and commercialize elvucitabine in mainland China, Hong Kong, and Taiwan. In Phase 2 clinical trials elvucitabine has demonstrated to be safe and well tolerated and to be efficacious in both HBV and HIV infected patients. Under the terms of the Agreement, the Licensee, through a subLicense Agreement with its Chinese joint venture, T & T Pharma Co., Ltd., formed with Tianjing Institute of Pharmaceutical Research  will assume all development and regulatory responsibility and associated costs for elvucitabine.

Field of Use
The rights granted apply to the Pharmaceutical Market relating to healthcare.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.